Emily M Stocking

This inventor holds 22 USPTO granted patents and 8 published patent applications, plus 4 CIPO patents and 9 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Janssen Pharmaceutica Nv, Neuropore Therapies, Inc., Global Cancer Technology Inc.. Active years: 2009-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Emily M Stocking. Retrieved from https://idiyas.com/inventor/emily-m-stocking

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 22 (Patent Applications = 8)

% Patents Active = 81.8

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 9 (Patent Applications = 13)

Average Co-Inventor Count = 3.4

ph-index = 3

Forward Citations = 33(Granted Patents)

Company Filing History:

9 out of 2,101

Janssen Pharmaceutica Nv

patents

8 out of 12

Neuropore Therapies, Inc.

patents

1 out of 1

Global Cancer Technology Inc.

patent

4. 1 out of 32

Janssen Pharmaceutica

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

PI3-Kinase Modulators

Orexin Receptor Modulators

Protein Aggregation Inhibitors

Heteroaryl Derivatives

Phenyl Sulfonyl Triazole

Morpholine Derivatives

Vps34 Inhibitors

Autophagy Pathways

TLR Signaling

Disubstituted Octahydropyrrolo

Tri-Substituted Aryl Derivatives

Bis-Heteroaryl Derivatives

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12637450 - Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways (2026-05-26),

2. 12378254 - Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators (2025-08-05),

3. 12049462 - Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways (2024-07-30),

4. 11708338 - Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof (2023-07-25),

5. 11667644 - Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators (2023-06-06),

6. 11492348 - Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways (2022-11-08),

7. 11299487 - Compounds and compositions as modulators of TLR signaling (2022-04-12),

8. 11236079 - Morpholine derivates as inhibitors of Vps34 (2022-02-01),

9. RE48841 - Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators (2021-12-06),

10. 11078196 - Heteroaryl amides as inhibitors of protein aggregation (2021-08-03),

11. 11059828 - Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators (2021-07-13),

12. 11008294 - Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof (2021-05-18),

13. 10975066 - Bis-heteroaryl derivatives as modulators of protein aggregation (2021-04-13),

14. 10501423 - Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof (2019-12-10),

15. 10358443 - Heteroaryl amides as inhibitors of protein aggregation (2019-07-23),

Title: The Innovations of Emily M. Stocking in Pharmaceutical Sciences

Introduction: Emily M. Stocking, based in Encinitas, CA, has made significant contributions to the field of pharmaceutical sciences, holding an impressive portfolio of 20 patents. Her work focuses on innovative compounds that target critical biological pathways, particularly those involved in various diseases.

Latest Patents: Among her latest patents, one key invention includes "Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways." This patent discusses the development of specific chemical compounds, pharmaceutical compositions, and their applications in modulating autophagy and regulating the PI3K-AKT-MTOR pathway. Another notable patent, "Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof," outlines novel compounds and their potential therapeutic applications.

Career Highlights: Emily has had a robust career in the pharmaceutical industry, working for reputable companies such as Janssen Pharmaceutica and Neuropore Therapies, Inc. Her expertise in medicinal chemistry has facilitated groundbreaking advancements in drug development.

Collaborations: Throughout her career, Emily has collaborated with esteemed colleagues, including Wolfgang J. Wrasidlo and Michael Anthony Letavic. These partnerships have further enhanced her research and contributed to the successful development of her patented innovations.

Conclusion: Emily M. Stocking’s contributions to pharmaceutical innovations highlight her commitment to addressing complex medical challenges. With a total of 20 patents, her research continues to pave the way for new therapeutic options and advancements in healthcare.

Profile summary based on public USPTO records.